Analyst predicts slow start for Leo Pharma's Adtralza in UK
The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.
by albert rønning-andersson, translated by catherine brett
Leo Pharma shouldn’t count on big sales of its atopic eczema drug Adtralza on the UK market – at least not to begin with.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
England and Wales reject Leo Pharma's eczema drug
For subscribers
